Systemic
|
Cardiovascular drugs* | 108 | 65 (58.3) | 449 | 128 (28.5) | <0.001 |
Hyperlipidaemia | 56 | 10 (17.9) | 448 | 28 (6.3) | 0.005 |
Anaemia | 87 | 7 (8.8) | 449 | 13 (2.9) | 0.013 |
Peripheral vascular disease | 98 | 7 (7.1) | 448 | 9 (2) | 0.014 |
Diabetes | 108 | 5 (4.6) | 449 | 55 (12.2) | 0.02 |
Female sex | 108 | 80 (74) | 449 | 279 (62) | 0.02 |
Bleeding diatheses | 101 | 3 (3.1) | 447 | 2 (0.4) | 0.046 |
Hypertension | 106 | 52 (49.1) | 449 | 186 (41.4) | >0.1 |
Heart Failure | 101 | 4 (4.0) | 449 | 25 (5.6) | >0.1 |
IHD | 101 | 12 (11.9) | 449 | 50 (11.1) | >0.1 |
CVA | 100 | 7 (7.0) | 449 | 35 (7.8) | >0.1 |
Respiratory disease | 105 | 13 (12.4) | 448 | 68 (15.2) | >0.1 |
Aspirin | 104 | 21 (20.2) | 449 | 109 (24.3) | >0.1 |
Warfarin | 105 | 6 (5.7) | 449 | 15 (3.3) | >0.1 |
Ophthalmic
|
Glaucoma | 108 | 35 (32.4) | 449 | 29 (6.5) | <0.001 |
Past ocular surgery | 107 | 6 (5.6) | 448 | 6 (1.3) | 0.015 |
Operative
|
Procedure | 109 | | 449 | | |
Phacoemulsification | | 83 (76.2) | | 415 (92.4) | >0.1 |
ECCE | | 12 (11.0) | | 26 (5.8) | 0.038 |
Conversion† | | 14 (12.8) | | 8 (1.8) | <0.001 |
LA types‡ | 105 | | 399 | | |
Peribulbar | | 47 (44.8) | | 284 (71.2) | <0.001 |
Sub-Tenon’s | | 45 (42.9) | | 83 (20.8) | <0.001 |
Topical | | 11 (10.5) | | 13 (3.3) | <0.001 |
Orbital compression | 93 | 49 (52.7) | 389 | 306 (78.7) | <0.001 |
PC rupture before SCH | 108 | 22 (20.4) | 435 | 20 (4.6) | <0.001 |
GA | 108 | 3 (2.8) | 447 | 47 (10.5) | 0.012 |
Consultant surgeon | 108 | 76 (70.4) | 448 | 257 (57.4) | 0.013 |
Right eye | 108 | 52 (48.1) | 449 | 254 (56.6) | >0.1 |
Scleral section | 108 | 10 (9.3) | 448 | 36 (8.0) | >0.1 |